Michelle Whirl‐Carrillo

17.2k total citations · 11 hit papers
103 papers, 9.3k citations indexed

About

Michelle Whirl‐Carrillo is a scholar working on Pharmacology, Genetics and Molecular Biology. According to data from OpenAlex, Michelle Whirl‐Carrillo has authored 103 papers receiving a total of 9.3k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Pharmacology, 32 papers in Genetics and 29 papers in Molecular Biology. Recurrent topics in Michelle Whirl‐Carrillo's work include Pharmacogenetics and Drug Metabolism (66 papers), Genomics and Rare Diseases (27 papers) and Pharmaceutical studies and practices (23 papers). Michelle Whirl‐Carrillo is often cited by papers focused on Pharmacogenetics and Drug Metabolism (66 papers), Genomics and Rare Diseases (27 papers) and Pharmaceutical studies and practices (23 papers). Michelle Whirl‐Carrillo collaborates with scholars based in United States, Canada and Spain. Michelle Whirl‐Carrillo's co-authors include Teri E. Klein, Katrin Sangkuhl, Russ B. Altman, Li Gong, Andrea Gaedigk, Caroline F. Thorn, Kelly E. Caudle, Ellen M. McDonagh, Joan M. Hebert and Stuart A. Scott and has published in prestigious journals such as Nucleic Acids Research, Journal of Biological Chemistry and SHILAP Revista de lepidopterología.

In The Last Decade

Michelle Whirl‐Carrillo

100 papers receiving 9.2k citations

Hit Papers

Pharmacogenomics Knowledg... 2011 2026 2016 2021 2012 2011 2017 2021 2018 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pharmacogenomics Knowledge for Personalized Medicine
    2012 1.3k citations Michelle Whirl‐Carrillo, Li Gong et al. Clinical Pharmacology & Therapeutics profile →
  2. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing
    2011 473 citations Li Gong, Michelle Whirl‐Carrillo et al. Clinical Pharmacology & Therapeutics profile →
  3. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics‐Guided Warfarin Dosing: 2017 Update
    2017 435 citations Li Gong, Michelle Whirl‐Carrillo et al. Clinical Pharmacology & Therapeutics profile →
  4. An Evidence‐Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine
    2021 410 citations Michelle Whirl‐Carrillo, Rachel Huddart et al. Clinical Pharmacology & Therapeutics profile →
  5. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update
    2018 403 citations Mary V. Relling, Matthias Schwab et al. Clinical Pharmacology & Therapeutics profile →
  6. Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group
    2019 369 citations Kelly E. Caudle, Katrin Sangkuhl et al. profile →
  7. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)
    2016 354 citations Kelly E. Caudle, Henry M. Dunnenberger et al. profile →
  8. Prediction of CYP2D6 phenotype from genotype across world populations
    2016 352 citations Andrea Gaedigk, Katrin Sangkuhl et al. profile →
  9. The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature Database
    2017 294 citations Andrea Gaedigk, Neil Miller et al. Clinical Pharmacology & Therapeutics profile →
  10. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy
    2018 237 citations Katrin Sangkuhl, Matthias Schwab et al. Clinical Pharmacology & Therapeutics profile →
  11. PharmVar GeneFocus: CYP2B6
    2021 178 citations Zeruesenay Desta, Li Gong et al. Clinical Pharmacology & Therapeutics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michelle Whirl‐Carrillo United States 45 5.3k 2.4k 2.2k 1.8k 1.5k 103 9.3k
Katrin Sangkuhl United States 40 4.4k 0.8× 2.1k 0.9× 1.6k 0.7× 1.1k 0.6× 1.2k 0.8× 70 8.6k
Stuart A. Scott United States 46 4.3k 0.8× 1.8k 0.8× 1.7k 0.8× 1.5k 0.8× 1.1k 0.7× 141 8.8k
Andrea Gaedigk United States 60 8.9k 1.7× 2.7k 1.2× 3.6k 1.6× 1.8k 1.0× 3.0k 2.0× 237 13.7k
Ann K. Daly United Kingdom 74 9.9k 1.9× 4.3k 1.8× 2.3k 1.0× 1.8k 1.0× 4.5k 3.0× 282 20.5k
David A. Flockhart United States 63 5.6k 1.0× 3.9k 1.7× 1.3k 0.6× 3.9k 2.2× 4.3k 2.9× 255 15.3k
Jürgen Brockmöller Germany 65 5.1k 1.0× 4.0k 1.7× 2.7k 1.2× 1.1k 0.6× 4.0k 2.7× 236 13.8k
Zeruesenay Desta United States 45 4.0k 0.7× 1.5k 0.6× 947 0.4× 2.5k 1.4× 2.4k 1.6× 171 8.6k
Jesse J. Swen Netherlands 39 3.0k 0.6× 1.3k 0.6× 1.4k 0.6× 866 0.5× 1.6k 1.1× 164 5.9k
Ron H. N. van Schaik Netherlands 53 2.8k 0.5× 2.1k 0.9× 2.2k 1.0× 779 0.4× 2.7k 1.8× 242 9.3k
Mikko Niemi Finland 64 5.5k 1.0× 2.5k 1.0× 3.2k 1.4× 872 0.5× 6.2k 4.1× 277 15.2k

Countries citing papers authored by Michelle Whirl‐Carrillo

Since Specialization
Citations

This map shows the geographic impact of Michelle Whirl‐Carrillo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michelle Whirl‐Carrillo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michelle Whirl‐Carrillo more than expected).

Fields of papers citing papers by Michelle Whirl‐Carrillo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michelle Whirl‐Carrillo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michelle Whirl‐Carrillo. The network helps show where Michelle Whirl‐Carrillo may publish in the future.

Co-authorship network of co-authors of Michelle Whirl‐Carrillo

This figure shows the co-authorship network connecting the top 25 collaborators of Michelle Whirl‐Carrillo. A scholar is included among the top collaborators of Michelle Whirl‐Carrillo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michelle Whirl‐Carrillo. Michelle Whirl‐Carrillo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Eadon, Michael T., David W. Hein, Michael Asger Andersen, et al.. (2025). Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy. Clinical Pharmacology & Therapeutics. 118(6). 1430–1436.
2.
Caudle, Kelly E., Michelle Whirl‐Carrillo, Mary V. Relling, et al.. (2025). Advancing Clinical Pharmacogenomics Worldwide Through the Clinical Pharmacogenetics Implementation Consortium ( CPIC ). Clinical Pharmacology & Therapeutics. 118(6). 1512–1522. 2 indexed citations
3.
Eum, Seenae, Zeruesenay Desta, Rachel F. Tyndale, et al.. (2024). Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy. Clinical Pharmacology & Therapeutics. 116(4). 932–938. 9 indexed citations
4.
Gong, Li, Michelle Whirl‐Carrillo, Stuart A. Scott, et al.. (2024). P179: The ClinGen Pharmacogenomics Working Group: Developing frameworks for evaluating pharmacogenomic gene validity and actionability. SHILAP Revista de lepidopterología. 2. 101076–101076. 1 indexed citations
5.
Pratt, Victoria M., Larisa H. Cavallari, Andrea Gaedigk, et al.. (2024). DPYD Genotyping Recommendations. Journal of Molecular Diagnostics. 26(10). 851–863. 21 indexed citations
6.
Oni‐Orisan, Akinyemi, Sony Tuteja, D. Max Smith, et al.. (2023). An Introductory Tutorial on Cardiovascular Pharmacogenetics for Healthcare Providers. Clinical Pharmacology & Therapeutics. 114(2). 275–287. 6 indexed citations
7.
Li, Binglan, Katrin Sangkuhl, Ryan Whaley, et al.. (2023). Frequencies of pharmacogenomic alleles across biogeographic groups in a large-scale biobank. The American Journal of Human Genetics. 110(10). 1628–1647. 17 indexed citations
8.
Gammal, Roseann S., Munir Pirmohamed, Andrew A. Somogyi, et al.. (2022). Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. Clinical Pharmacology & Therapeutics. 113(5). 973–985. 28 indexed citations
9.
Li, Binglan, Katrin Sangkuhl, Ryan Whaley, et al.. (2022). How to Run the Pharmacogenomics Clinical Annotation Tool (PharmCAT). Clinical Pharmacology & Therapeutics. 113(5). 1036–1047. 7 indexed citations
10.
Whirl‐Carrillo, Michelle, Rachel Huddart, Li Gong, et al.. (2021). An Evidence‐Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine. Clinical Pharmacology & Therapeutics. 110(3). 563–572. 410 indexed citations breakdown →
11.
Pratt, Victoria M., Larisa H. Cavallari, Andria L. Del Tredici, et al.. (2021). Recommendations for Clinical CYP2D6 Genotyping Allele Selection. Journal of Molecular Diagnostics. 23(9). 1047–1064. 97 indexed citations
12.
Pratt, Victoria M., Larisa H. Cavallari, Andria L. Del Tredici, et al.. (2019). Recommendations for Clinical CYP2C9 Genotyping Allele Selection: A Joint Recommendation of the Association for Molecular Pathology and College of American Pathologists. Publisher. 12 indexed citations
13.
Desta, Zeruesenay, Roseann S. Gammal, Li Gong, et al.. (2019). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz‐Containing Antiretroviral Therapy. PMC. 19 indexed citations
14.
Huddart, Rachel, Katrin Sangkuhl, Michelle Whirl‐Carrillo, & Teri E. Klein. (2019). Are Randomized Controlled Trials Necessary to Establish the Value of Implementing Pharmacogenomics in the Clinic?. Clinical Pharmacology & Therapeutics. 106(2). 284–286. 27 indexed citations
15.
Phillips, Elizabeth J., Chonlaphat Sukasem, Michelle Whirl‐Carrillo, et al.. (2018). Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update. Clinical Pharmacology & Therapeutics. 103(4). 574–581. 182 indexed citations
16.
Yang, Jun J., Michelle Whirl‐Carrillo, Stuart A. Scott, et al.. (2018). Pharmacogene Variation Consortium Gene Introduction: NUDT15. Clinical Pharmacology & Therapeutics. 105(5). 1091–1094. 40 indexed citations
17.
Relling, Mary V., Matthias Schwab, Michelle Whirl‐Carrillo, et al.. (2018). Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clinical Pharmacology & Therapeutics. 105(5). 1095–1105. 403 indexed citations breakdown →
18.
Caudle, Kelly E., Allan E. Rettie, Michelle Whirl‐Carrillo, et al.. (2014). Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.. The Medicine Forum. 96(5). 542. 6 indexed citations
19.
Gabashvili, Irene S., et al.. (2003). Ribosomal dynamics inferred from variations in experimental measurements. RNA. 9(11). 1301–1307. 14 indexed citations
20.
Roth, David A., et al.. (1995). Mutagenesis of Vitamin K-dependent Carboxylase Demonstrates a Carboxyl Terminus-mediated Interaction with Vitamin K Hydroquinone. Journal of Biological Chemistry. 270(10). 5305–5311. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Katrin Sangkuhl Breakdown of academic impact, for papers by Stuart A. Scott Breakdown of academic impact, for papers by Andrea Gaedigk Breakdown of academic impact, for papers by Ann K. Daly Breakdown of academic impact, for papers by David A. Flockhart Breakdown of academic impact, for papers by Jürgen Brockmöller Breakdown of academic impact, for papers by Zeruesenay Desta Breakdown of academic impact, for papers by Jesse J. Swen Breakdown of academic impact, for papers by Ron H. N. van Schaik Breakdown of academic impact, for papers by Mikko Niemi
Rankless by CCL
2026